NRx Pharmaceuticals

NRXP

Biotechnology · Healthcare

Price

$3.56

+0.05 (+1.42%)

Market Cap

$61.5M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count falling — buybacks

−54.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 46.9M (2021) → 21.4M (2025)

Winston Score History

The full picture

NRx Pharmaceuticals is a small biotech company focused on developing drugs for serious mental health conditions and life-threatening illnesses. Its lead drug candidate, NRX-101, targets bipolar depression with suicidal thoughts — a condition with very few approved treatments. The company also worked on Zyesami (aviptadil) for critical COVID-19 patients, though that program faced regulatory setbacks.

NRx earns minimal revenue today and operates at a steep loss, which is typical for early-stage drug developers that spend heavily on clinical trials before any product reaches the market. The company operates primarily in the United States and is very small, with a market cap around $100 million. Its main competitive angle is targeting underserved psychiatric conditions where approved options are limited. The biggest risk is regulatory — if NRX-101 fails to win FDA approval or faces delays in clinical trials, the company has little else to fall back on, making it highly dependent on a single drug's success.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+55.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$4M/ year

↓ Declining (-39% vs prior year)

308.3% of revenue

17.1x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

16.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 months

$27M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

NRx Pharmaceuticals has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

23.4%

Thin — 23.4% gross margin

Profit after running costs

Operating Margin

-590.8%

Losing money on operations — -590.8%

Return on the money invested

ROCE

-2688.0%

Weak — -2688.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-609.0%

Burning cash (-609.0%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial